|
[1]
|
黄小琪. 子宫内膜癌与K-ras基因突变的研究[J]. 细胞与分子免疫学杂志, 2010(7): 701-702.
|
|
[2]
|
杨静, 薛敏. PTEN基因突变及蛋白表达与子宫内膜癌的相关性研究[J]. 现代肿瘤医学, 2008(5): 810-812.
|
|
[3]
|
魏松锋, 黄亮, 张艳, 程文元, 高明. PTEN、Smad4在肿瘤发生、发展中作用的研究进展[J]. 现代肿瘤医学, 2011(2): 376-379.
|
|
[4]
|
李志伟, 李彩红, 张智慧, 席丰. 子宫内膜癌中PTEN蛋白、P-AKT蛋白的表达及意义[J]. 现代肿瘤医学, 2013(03): 633-635.
|
|
[5]
|
邓开玉, 田小英. PTEN和K-ras与子宫内膜癌关系的研究进展[J]. 中华肿瘤防治杂志, 2011(15): 1217-1220.
|
|
[6]
|
郎博娟, 马金阳, 胡余昌, 胡海燕, 王晓璐. 子宫内膜癌组织her-2/neu过表达临床及病理意义的Meta分析[J]. 数理医药学杂志, 2015(1): 49-52.
|
|
[7]
|
甘露, 许嵩. PTEN和P53蛋白与子宫内膜癌发生发展的相关性研究[J]. 临床和实验医学杂志, 2016(21): 2114-2117.
|
|
[8]
|
赵桂凤, 张艳红. PTEN和C-erbB-2蛋白在子宫内膜癌的表达及临床意义[J]. 中国优生与遗传杂志, 2013(6): 39-40+62.
|
|
[9]
|
朱丽霞, 刘琴, 李海, 徐松. STAT-3与PTEN基因蛋白在子宫内膜癌中的表达及意义[J]. 现代中西医结合杂志, 2014(8): 799-801+4.
|
|
[10]
|
张晓明, 梁英, 董颖, 张莹, 王颖, 孟佚婷, 等. 子宫内膜癌中p-AKT与PTEN、P53、HER-2表达的相关性及意义[J]. 北京大学学报(医学版), 2012(1): 135-141.
|
|
[11]
|
Tirmazy, S.H., Barthakur, U., El-Modir, A., Anwar, S. and Fernando, I. (2014) Chemotherapy for Advanced Endometrial Cancer with Carboplatin and Epirubicin. Anticancer Research, 34, 3793-3798.
|
|
[12]
|
崔慢慢. 妇科肿瘤患者化疗后不良反应的临床表现及治疗策略[J]. 检验医学与临床, 2014(3): 292-293 + 296.
|
|
[13]
|
张婵娟. 妇科癌症术后化疗患者创伤后应激障碍症状及影响因素[D]: [硕士学位论文]. 济南: 山东大学, 2013.
|
|
[14]
|
谢娅, 孙红敏, 张颖, 史明星. 二甲双胍在子宫内膜癌细胞中增强紫杉醇的药物敏感性[J]. 中国医药指南, 2014(13): 73-75.
|
|
[15]
|
Zou, J., Hong, L., Luo, C., Li, Z., Zhu, Y., Huang, T., et al. (2016) Metformin Inhibits Estrogen-Dependent Endometrial Cancer Cell Growth by Activating the AMPK-FOXO1 Signal Pathway. Cancer Science, 107, 1806-1817.
https://doi.org/10.1111/cas.13083
|
|
[16]
|
Wallbillich, J.J., Josyula, S., Saini, U., Zingarelli, R.A., Dorayappan, K.D., Riley, M.K., et al. (2017) High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer. PLoS ONE, 12, e0170318.
https://doi.org/10.1371/journal.pone.0170318
|
|
[17]
|
Winship, A., Van Sinderen, M., Rainczuk, K. and Dimitriadis, E. (2017) Therapeutically Blocking Interleukin-11 Receptor-Alpha Enhances Doxorubicin Cytotoxicity in High Grade Type I Endometrioid Tumours. Oncotarget, 8, 22716-22729.
https://doi.org/10.18632/oncotarget.15187
|
|
[18]
|
胡美丽, 李利, 王晓玲, 康山. 三氧化二砷对人子宫内膜癌移植瘤的影响[J]. 河北医科大学学报, 2014(11): 1281-1284.
|
|
[19]
|
冯振中, 武世伍, 李楠, 蔡兆根, 吕秀红, 陈嘉薇. COX-2选择性抑制剂塞来昔布联合PPAR-γ配体罗格列酮治疗子宫内膜癌的实验研究[J]. 华中科技大学学报(医学版), 2014(6): 619-625.
|
|
[20]
|
Rabinovich, A. (2016) Neo-Adjuvant Chemotherapy for Advanced Stage Endometrial Carcinoma: A Glimmer of Hope in Select Patients. Archives of Gynecology and Obstetrics, 293, 47-53.
https://doi.org/10.1007/s00404-015-3841-8
|
|
[21]
|
Vandenput, I., Van Calster, B., Capoen, A., Leunen, K., Berteloot, P., Neven, P., et al. (2009) Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery in Patients with Serous Endometrial Cancer with Transperitoneal Spread (Stage IV): A New Preferred Treatment? British Journal of Cancer, 101, 244-249.
https://doi.org/10.1038/sj.bjc.6605157
|
|
[22]
|
Wilkinson-Ryan, I., Frolova, A.I., Liu, J., Stewart Massad, L., Thaker, P.H., Powell, M.A., et al. (2015) Neoadjuvant Chemotherapy versus Primary Cytoreductive Surgery for Stage IV Uterine Serous Carcinoma. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 25, 63-68.
https://doi.org/10.1097/IGC.0000000000000321
|
|
[23]
|
Boisen, M.M., Vargo, J.A., Beriwal, S., Sukumvanich, P., Olawaiye, A.B., Kelley, J.L., et al. (2016) Surgical Outcomes of Patients Undergoing Extrafascial Hysterectomy after Neoadjuvant Radiotherapy with or without Chemotherapy for Locally Advanced Endometrial Cancer Clinically Extending to the Cervix or Parametria. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 27, 1149-1154.
|
|
[24]
|
张和平, 金海红, 王智文. P-糖蛋白与新辅助化疗治疗子宫内膜癌疗效的相关性分析[J]. 中国肿瘤临床与康复, 2013(2): 116-118.
|
|
[25]
|
Eritja, N., Domingo, M., Dosil, M.A., Mirantes, C., Santacana, M., Valls, J., et al. (2014) Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells. Molecular Cancer Therapeutics, 13, 776-787.
https://doi.org/10.1158/1535-7163.MCT-13-0794
|
|
[26]
|
Eritja, N., Chen, B.J., Rodriguez-Barrueco, R., Santacana, M., Gatius, S., Vidal, A., et al. (2017) Autophagy Orchestrates Adaptive Responses to Targeted Therapy in Endometrial Cancer. Autophagy, 1-17.
https://doi.org/10.1080/15548627.2016.1271512
|
|
[27]
|
Kim, D.H., Kwak, Y., Kim, N.D. and Sim, T. (2016) Antitumor Effects and Molecular Mechanisms of Ponatinib on Endometrial Cancer Cells Harboring Activating FGFR2 Mutations. Cancer Biology & Therapy, 17, 65-78.
https://doi.org/10.1080/15384047.2015.1108492
|
|
[28]
|
Aghajanian, C., Sill, M.W., Darcy, K.M., Greer, B., McMeekin, D.S., Rose, P.G., et al. (2011) Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 29, 2259-2265.
https://doi.org/10.1200/JCO.2010.32.6397
|
|
[29]
|
沈媛, 陆琳, 王晓玉. 赫赛汀诱导子宫内膜癌Ishikawa细胞凋亡并增强其对化疗的敏感性[J]. 中国病理生理杂志, 2015(9): 1568-1571.
|
|
[30]
|
Groeneweg, J.W., Hernandez, S.F., Byron, V.F., DiGloria, C.M., Lopez, H., Scialabba, V., et al. (2014) Dual HER2 Targeting Impedes Growth of HER2 Gene-Amplified Uterine Serous Carcinoma Xenografts. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 20, 6517-6528.
https://doi.org/10.1158/1078-0432.CCR-14-1647
|
|
[31]
|
Koskas, M., Depreeuw, J., Moens, S., Annibali, D., Cuppens, T., Moerman, P., et al. (2016) Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-Positive Endometrial Carcinoma. Anticancer Research, 36, 5381-5384.
https://doi.org/10.21873/anticanres.11112
|
|
[32]
|
刘佳, 邓燕杰, 李秀娟, 燕秋. 人参皂甙Rg3联合LewisY单克隆抗体对子宫内膜癌的治疗作用[J]. 中国妇幼保健, 2014(14): 2248-2252.
|
|
[33]
|
张培培, 张国利, 田园, 付玉和, 赵鑫. 抗促黄体激素释放激素受体单克隆抗体对人子宫内膜癌Ishikawa细胞增殖及凋亡的影响[J]. 中国生物制品学杂志, 2016(3): 275-278.
|
|
[34]
|
刁振宇, 卢悟广, 曹鹏, 胡云龙, 周星, 薛平平, 等. EGFR纳米抗体抑制雌激素依赖的人子宫内膜癌Ishikawa细胞的增殖与迁移[J]. 药学学报, 2012(10): 1341-1346.
|
|
[35]
|
曹楚楚, 黄炉仁, 傅芬. PI3K/Akt/mTOR信号通路及其相关基因突变与子宫内膜癌靶向性药物治疗的研究进展[J]. 基础医学与临床, 2017(1): 118-122.
|
|
[36]
|
Maira, S.M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., et al. (2012) Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor. Molecular Cancer Therapeutics, 11, 317-328.
https://doi.org/10.1158/1535-7163.MCT-11-0474
|
|
[37]
|
Temkin, S.M., Yamada, S.D. and Fleming, G.F. (2010) A Phase I Study of Weekly Temsirolimus and Topotecan in the Treatment of Advanced and/or Recurrent Gynecologic Malignancies. Gynecologic Oncology, 117, 473-476.
|
|
[38]
|
Korets, S.B., Musa, F., Curtin, J., Blank, S.V. and Schneider, R.J. (2014) Dual mTORC1/2 Inhibition in a Preclinical Xenograft Tumor Model of Endometrial Cancer. Gynecologic Oncology, 132, 468-473.
|
|
[39]
|
Vlahovic, G., Meadows, K.L., Uronis, H.E., Morse, M.A., Blobe, G.C., Riedel, R.F., et al. (2012) A Phase I Study of Bevacizumab, Everolimus and Panitumumab in Advanced Solid Tumors. Cancer Chemotherapy and Pharmacology, 70, 95-102.
https://doi.org/10.1007/s00280-012-1889-8
|
|
[40]
|
Colombo, N., McMeekin, D.S., Schwartz, P.E., Sessa, C., Gehrig, P.A., Holloway, R., et al. (2013) Ridaforolimus as a Single Agent in Advanced Endometrial Cancer: Results of a Single-Arm, Phase 2 Trial. British Journal of Cancer, 108, 1021-1026.
https://doi.org/10.1038/bjc.2013.59
|
|
[41]
|
Xu, C., Li, X., Li, T., Wang, X., Yang, Y., Xiao, L., et al. (2011) Combination Effects of Paclitaxel with Signaling Inhibitors in Endometrial Cancer Cells. Asian Pacific Journal of Cancer Prevention, 12, 2951-2957.
|
|
[42]
|
Mendivil, A., Zhou, C., Cantrell, L.A., Gehrig, P.A., Malloy, K.M., Blok, L.J., et al. (2011) AMG 479, a Novel IGF-1-R Antibody, Inhibits Endometrial Cancer Cell Proliferation through Disruption of the PI3K/Akt and MAPK Pathways. Reproductive Sciences, 18, 832-841.
https://doi.org/10.1177/1933719111398501
|
|
[43]
|
Li, Y., Zhang, Z., Zhang, X., Lin, Y., Luo, T., Xiao, Z., et al. (2016) A Dual PI3K/AKT/mTOR Signaling Inhibitor miR-99a Suppresses Endometrial Carcinoma. American Journal of Translational Research, 8, 719-731.
|
|
[44]
|
Vogel, R.I., Pulver, T., Heilmann, W., Mooneyham, A., Mullany, S., Zhao, X., et al. (2016) USP14 Is a Predictor of Recurrence in Endometrial Cancer and a Molecular Target for Endometrial Cancer Treatment. Oncotarget, 7, 30962-30976.
https://doi.org/10.18632/oncotarget.8821
|
|
[45]
|
Chuwa, A.H., Sone, K., Oda, K., Ikeda, Y., Fukuda, T., Wada-Hiraike, O., et al. (2016) Significance of Survivin as a Prognostic Factor and a Therapeutic Target in Endometrial Cancer. Gynecologic Oncology, 141, 564-569.
|
|
[46]
|
吕斯迹, 殷怡华. 孕激素在子宫内膜癌前期病变和子宫内膜癌中的应用[J]. 世界临床药物, 2014(11): 655-658.
|
|
[47]
|
王佳玉, 徐兵河. 氟维司群治疗绝经后激素受体阳性晚期乳腺癌的研究进展[J]. 中国癌症杂志, 2016(5): 471-475.
|
|
[48]
|
卢红阳, 蔡菊芬, 王晓稼. 氟维司群临床应用研究进展[J]. 实用肿瘤杂志, 2012(5): 562-564.
|
|
[49]
|
Lux, M.P., Wenkel, E.M., Beckmann, K., Beckmann, M.W. and Thiel, F. (2006) Fulvestrant: A Further Treatment Option for Patients with Metastatic Uterine Cancer? Onkologie, 29, 577-580.
https://doi.org/10.1159/000096541
|
|
[50]
|
Grevers, X., Grundy, A., Poirier, A.E., Khandwala, F., Feldman, M., Friedenreich, C.M., et al. (2016) Cancer Incidence Attributable to the Use of Oral Contraceptives and Hormone Therapy in Alberta in 2012. CMAJ Open, 4, e754-e759.
https://doi.org/10.9778/cmajo.20160046
|
|
[51]
|
王国艳. 宫腔镜电切术联合孕激素治疗早期子宫内膜癌的疗效分析[J]. 中国医药指南, 2017(3): 74-75.
|
|
[52]
|
邓柳枝, 叶青剑, 李小毛. 孕激素或左炔诺孕酮宫内缓释系统治疗子宫内膜癌的疗效分析[J]. 现代妇产科进展, 2013(2): 135-138.
|
|
[53]
|
俞梅, 沈铿, 杨佳欣, 黄惠芳, 吴鸣, 潘凌亚, 等. 高分化子宫内膜样癌及子宫内膜重度不典型增生患者孕激素治疗的临床分析[J]. 中华妇产科杂志, 2006(4): 242-245.
|
|
[54]
|
Wan, J., Gao, Y., Zeng, K., Yin, Y., Zhao, M., Wei, J., et al. (2016) The Levels of the Sex Hormones Are Not Different between Type 1 and Type 2 Endometrial Cancer. Scientific Reports, 6, 39744.
https://doi.org/10.1038/srep39744
|
|
[55]
|
黄彩梅, 夏亦冬, 胡国华. 中药治疗子宫内膜癌作用机制研究进展[J]. 吉林中医药, 2015(9): 969-972.
|
|
[56]
|
黄文玲. 葛根提取物对子宫内膜癌细胞体外增殖的影响及机理研究[D]: [博士学位论文]. 北京: 北京中医药大学, 2006.
|
|
[57]
|
尹雯. 紫草素对子宫内膜癌Ishikawa细胞增殖和凋亡的影响及其机制研究[J]. 现代中西医结合杂志, 2016(32): 3548-3551.
|
|
[58]
|
周晓芳, 黄晓龙, 陈宜涛, 俞欢. 枸杞多糖对紫杉醇治疗子宫内膜癌的增效减毒机制研究[J]. 中国临床药理学与治疗学, 2016(12): 1354-1360.
|
|
[59]
|
阳桂华. 桂枝茯苓丸配合培美曲塞奈达铂治疗晚期子宫内膜癌近期疗效观察[J]. 陕西中医, 2014(12): 1644-1646.
|
|
[60]
|
常培江, 张国英, 栾福玉. 黄芪注射液辅助治疗在早期高危子宫内膜癌化疗增效减毒的研究[J]. 中国中医急症, 2016(9): 1822-1825.
|